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Abstract
 .  .An endo 1-4 -b-glucanase gene C6.5 from Bacillus subtilis has been expressed in Chinese hamster ovary CHO cells
and pancreatic 266-6 cells. The fusion gene, stably transfected into CHO cells consisted of the mouse Amy-2.2 signal
peptide coding sequence and the endoglucanase gene C6.5 transcribed from the early SV40 promoterrenhancer, using the
dihydrofolate reductase gene as a selective marker. The gene construct transfected into pancreatic 266-6 cells consisted of
the mouse Amy-2.2 promoterrenhancer and signal peptide coding sequence and the same C6.5 sequences using the
 .xanthine-guanine phosphoribosyl transferase gene gpt as the selective marker. The stably transfected CHO cells
synthesized endoglucanase at 1.1 Urmg cell protein in a 72 h culture, with 89% of the activity secreted into the culture
fluid in a glycosylated form of 66 kDa as compared with the unglycosylated 53 kDa form expressed in E. coli.
Glycosylation did not change the specific activity, protease resistance, or cellulose binding of the endoglucanase as
compared to the unglycosylated form of the enzyme from E. coli. The level of expression in the stably transfected
pancreatic cells was substantially lower at 0.3 mUrmg cell protein with all detectable activity present in the culture fluid.
The secreted enzyme from pancreatic cells was glycosylated with a mass similar to that secreted from CHO cells.
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1. Introduction
Monogastric animals do not synthesize enzymes
that cleave plant structural polysaccharides. Conse-
quently the high content of glucan and arabinoxylan
in cereal grains produces high viscosity of intestinal
contents which in turn can cause diarrhea and reduces
digestibility of other nutrients, and this is particularly
w xnoted for poultry 1 . Generation of transgenic domes-
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tic animals able to synthesize their own plant cell
wall-digesting enzymes could provide a substantial
benefit to the animal industry.
Many aspects of the synthesis and secretion of
bacterial proteins in eukaryotic cells are poorly un-
derstood. For instance, post-translational modification
of proteins by glycosylation is very common in eu-
w xkaryotic cells 2 and studies of structure-function
relationships in glycoproteins have demonstrated that
the carbohydrate moiety confers important biological
properties such as immunogenicity, solubility, protec-
tion from proteolytic attack, and maintenance of a
w xbiologically active conformation 3 . It is, however,
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hard to predict how glycosylation will affect the
nature of normally unmodified prokaryotic proteins
expressed in eukaryotic cells. For example, glyco-
 .sylation of 1,3-1,4 -b-glucanase of Bacillus amy-
 .loliquefaciens, 1,3-1,4 -b-glucanase of Bacillus
macerans and some hybrid enzymes in yeast have
increased the enzyme thermostability, but one of the
hybrid enzyme with a similar primary structure was
less thermostable when it was glycosylated in the
w xsame yeast strain 4 . Studies on endoglucanase E of
w xClostridium thermocellum 5 synthesized in Chinese
 .hamster ovary CHO cells have also shown that the
enzyme is glycosylated and that it is functionally
w xactive 6,7 .
Pancreatic cells in culture provide a vehicle for
investigating the glycosylation and function of bacte-
rial glycanolytic enzymes for future applications in
 .transgenic animal models. A cloned endo 1-4 -b-
w xglucanase C6.5 of Bacillus subtilis 8 has shown
activity against barley-b-glucan and resistance to in-
 .testinal contents of pigs and mice unpublished data .
 .In this study, we have fused the endo 1-4 -b-
glucanase gene C6.5 to the amylase secretory peptide
coding sequence and expressed it in CHO and pan-
w xcreatic 266-6 mammalian cells 9 under the tran-
scriptional control of the SV40 and amylase promot-
ers, respectively.
2. Materials and methods
2.1. Plasmid construction
The transgene AmyC6.5 for expression in pancre-
atic 266-6 cells was constructed using the plasmid
pAM2.5r1.5 containing the mouse a-amylase gene
 . w xAmy-2.2 sequence a gift from M.H. Meisler 10 .
The plasmid pAM2.5r1.5 was cleaved with Taq I
and the two fragments, a 2.5 kbp fragment containing
the Amy-2.2 promoterrenhancer and 98 bp of 5X
coding sequence and a 2.1 kbp fragment containing
105 bp of the Amy-2.2 3X coding sequence and
 .polyadenylation polyA tail, were each cloned into
pBluescriptII KSq at the Cla I site resulting in
pAmyrKS2.5 and pAmyrKS2.1. pAmyrKS2.5 con-
 .tained the polycloning site PCS downstream from
the Amy-2.2 promoterrenhancer and signal coding
sequence, and pAmyrKS2.1 contained the PCS up-
stream of the amylase sequence. For construction of
the endoglucanase transgene the 1.4 kbp Nae I-
w xHin dIII fragment of pC6.5 8 was first cloned into
pBluescriptII KSq at the Sma IrHin dIII sites, then
cleaved at the flanking restriction sites Bam HIrSal I
and cloned into pUC19 cleaved with the same restric-
tion enzymes. The Sma I-Hin dIII fragment contain-
ing the glucanase gene was then cloned into
pAmyrKS2.1 digested with the same enzymes. Fi-
nally, a Sma I-Bgl II fragment containing the C6.5
sequence, Amy-2.2 3X sequence and the polyA tail,
was cloned into the PCS of pAmyrKS2.5 at Eco RV
and Bam HI, resulting in pAmyC6.5. For selection in
266-6 cells, the construct in Bgl IIrXba I fragment
 . w xwas cloned into pRSV-gpt from ATCC 11 con-
taining the E. coli xanthine-guanine phosphoribosyl
 .transferase gene gpt , at the Bam HI site with
Klenow-filled ends in both insert and vector Fig.
.1B .
The transgene SVAC6.5 for expression in CHO
cells was constructed as below. Firstly, the Amy-2.2
sequences coding for a signal peptide was amplified
from pAM2.5r1.5 by PCR using primers
5XGAATGAAGTTCGTTCTGC3X and 5XGCAAGCT-
TGTCATATTGAGC3X annealing to y1 to 54 bp
 . Xfrom ATG of Amy-2.2, with 1 bp overhang at the 5
end and 8 bp at the 3X end including a Hin dIII
restriction site. The amplified fragment was cloned,
as a blunt end fragment, into pVS-b-galactosidase
 . w xfrom Promega 12 downstream of the early SV40
promoter at Bam HI and Hin dIII sites after filling of
the two ends with Klenow polymerase. Then the 0.9
kbp Eco RI-Hin dIII fragment containing the SV40
promoterrenhancer and the signal peptide coding
sequence was cloned into pAmyC6.5 at Sal IrHin dIII
sites to replace the Amy-2.2 promoterrenhancer with
the early SV40 promoterrenhancer after filling of the
Eco RI and Sal I sites in the insert and vector, result-
ing in pSVAC6.5. For selection in cell culture, the
 .construct was cloned into pSV2-dhfr from ATCC
w x13 containing a mouse dihydrofolate reductase gene
 .  .dhfr , at the Bam HI site Fig. 1A .
pGEX-C6.5, having the C6.5 endoglucanase cod-
ing sequence fused to the glutathione S-transferase
 .GST gene and pGEX-AC6.5 containing the same
sequences coding for the extra N-terminal amino
acids as in pAmyC6.5 were constructed based on a
truncated C6.5 clone. A DNA fragment coding for a
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truncated C6.5 from the 1st to 312th amino acid of
.mature C6.5 was amplified by PCR using primers
5X CGGAATTCGCAGGGACAAAAACGCCAG3X
and 5X CGGGATCCTTATTCAGGAATGTCCT-
TCGTCG3X with an Eco RI site introduced at the 5X
end and a stop codon and a Bam HI site introduced at
the 3X end. This fragment was digested by Eco RI
 . partial and Bam HI and cloned into pMAL-p2 New
. w xEngland Biolabs 14 digested by the same enzymes.
The insert was excised as a 0.5 kbp Eco RI-Sal I
fragment and cloned into pGEX-4T-1 Pharmacia
. w xBiotech 15 . The pGEX-C6.5 containing the intact
gene coding for the mature glucanase was obtained
by replacing the Eco RI-Sal I fragment in 3X-end of
the insert with the Eco RI-Hin dIII fragment from
pAmyC6.5 after filling of the Sal I and Hin dIII sites
 .Fig. 1C . The pGEX-AC6.5 was obtained by replac-
ing the 5X Eco RI fragment of pGEX-C6.5 with a
PCR-amplified fragment from pAmyC6.5 using
primers 5XGACGAATTCCAATATGACCCACA-
TACTTC3X and 5XGGCTTCACATTTCCTTG3X after
 .Eco RI digestion Fig. 1D . All the PCR-amplified
sequences were confirmed by sequencing.
2.2. Cell culture, DNA transfection and cell line
selection
CHO cells deficient in dihydrofolate reductase
 y. w xCHO-dhfr 16 were maintained in Iscove’s modi-
 .  .fied Dulbecco’s medium IMDM GIBCO BRL
Fig. 1. Transgenes and vectors used for expression of the endoglucanase gene C6.5 in CHO and 266-6 cells, and in E. coli. C6.5 is the
endoglucanase gene from B. subtilis. AC6.5 is the same gene with a partial amylase sequence fused at the 5X end. The 5X sequence of the
fusion gene and the predicted N-terminal amino acid sequence are shown in A and B. The putative cleavage site is indicated by an
arrowhead and the synthetic amino acids introduced during cloning are underlined. Common restriction enzyme sites used in the
construction of various plasmids included; Bg, Bgl II; Bm, Bam HI; Cla, Cla I; H, Hin dIII; Kpn, Kpn I; Nae, Nae I; Not, Not I; Nru,
Nru I; R1, Eco RI; Rv, Eco RV; Sal, Sal I; Sm, Sma I; Taq, Taq I; Xh, Xho I.
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 .containing penicillin, streptomycin, 10% vrv fetal
bovine serum, 16 mM thymidine and 100 mM hy-
 .poxanthine Sigma TH supplement . Mouse pancre-
atic 266-6 cells were grown in Dulbecco’s modified
 .  .medium DMEM GIBCO BRL containing the same
supplements as in IMDM except for the TH supple-
w xment 17 .
Subconfluent cultures of CHO-dhfry and 266-6 on
2=50 mm plates were transfected with 10 mg of
plasmid DNA prepared through double CsCl purifica-
tion, after coprecipitation with calcium phosphate
w x18,19 . After 18–20 h the precipitates were washed
off with fresh growth media and the cells were
incubated for a further 24 h. The transfected CHO
cells were selected in the growth medium without TH
supplement for about 3 weeks with changes of the
selective medium every 3 days until individual resis-
tant colonies formed. Initial transformants were
pooled and further selected in increasing concentra-
 .tions of methotrexate 0.1, 0.2, and 0.5 mM accord-
w xing to Hall et al. 6 . The transfected 266-6 cells were
selected by adding 250 mgrml xanthine, 13.6 mgrml
hypoxanthine and 2.5 mgrml mycophenolic acid in
the growth medium.
2.3. DNA and RNA analysis
Total cell RNA and DNA were isolated from
3-day cultured cells by the TRIzole method GIBCO
. w xBRL 20 following the protocol from the manufac-
turer. The transgenes were identified by PCR using a
primer pair of 5XCCAGTAGCCAAGAATGGC-
CAGCTTAGC3X and 5XCGGCAGCATCATTCA-
CATCCTGGCTCC3X to amplify a 0.5 kbp fragment
using an annealing temperature of 558C for 40 cycles.
The transcripts were identified by RT-PCR using the
SuperScripte Preamplification system kit GIBCO
.BRL and the same pair of primers with the same
condition as in PCR analysis.
2.4. Preparation, purification and analysis of the
transgene products
Unless otherwise indicated, enzymes from 3-day
old animal cell cultures were used. The culture
medium was collected and clarified by centrifugation
followed by dialysis in 50 mM sodium phosphate
 .buffer pH 6.5 at 48C for at least 24 h with several
changes of buffer. The cell monolayer was washed
twice with phosphate-buffered saline and collected in
50 mM sodium phosphate buffer, pH 6.5 1.5 ml per
.5 ml of culture and sonicated to obtain a cell extract.
Enzymes from pGEX clones in E. coli were puri-
fied first by affinity chromatography using Glu-
tathione Sepharose 4B following the protocol of the
 .manufacturer Pharmacia Biotech , then by gel filtra-
tion chromatography using a 5=50 cm column of
 .Bio-Gel P100 Bio-Rad Laboratories . The chro-
matography was performed at 5 mlrh, the fractions
 .12 ml each with activity were pooled and concen-
trated by using PM-10 ultrafiltration membrane
 .Amicon in a concentration cell. Purification of the
secreted endoglucanase from CHO cells, 266-6 cells
or E. coli was carried out by immuno-affinity chro-
matography. First mono-specific antibodies against
C6.5 were purified from rabbit polyclonal anti-C6.5
serum by immuno-affinity chromatography using the
purified C6.5 from the pGEX system coupled to
 .CNBr-activated Sepharose 4B Pharmacia Biotech .
A 6 mg amount of purified C6.5 1 mgrml in 0.1 M
.NaHCO r0.5 M NaCl, pH 8.3 was coupled to 0.3 g3
CNBr-activated Sepharose 4B for 2.5 h at room
temperature and washed according to the instruction
of the manufacturer. Following a wash with 15 ml of
PBS buffer, the gel was mixed with 2.7 ml of anti-
C6.5 serum at 48C overnight and transferred to a
 .small polypropylene column Novagen . The gel was
washed with 10 ml of PBS and 10 mM NaH PO ,2 4
pH 6.8, the bound antibody was eluted by 0.1 M
glycine buffer, pH 2.5 and 1 ml fractions collected in
test tubes containing 16 ml each of 1 M Na CO to2 3
bring the pH to neutral. The purified anti-C6.5 anti-
 .body 2.2 mg was dialyzed in 0.1 M NaHCO , pH3
8.0, and biotinylated with biotinamido caproate N-hy-
 .droxysuccimide ester 400 nmolrmg , following the
w xprocedure of Gretch et al. 21 . It was then used for
the next step of immuno-affinity chromatography to
purify the endoglucanase from CHO, 266-6 or E. coli
culture fluid. The biotinylated anti-C6.5 was reacted
with 12 ml of concentrated culture fluid from 80 ml
of CHO cell culture overnight at 48C in the same
w xbuffer as that described by Gretch et al. 21 without
 .SDS. One ml of streptavidin-agarose Sigma was
then added and allowed to react under gentle mixing
for 2.5 h at 48C. After extensive washing with PBS
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containing 0.1% NP-40 and 100 mgrml PMSF fol-
lowed by 14 ml of 10 mM sodium phosphate buffer
pH 7.2, the bound enzyme was eluted by 3.5 M
MgCl in 10 mM sodium phosphate buffer, pH 7.22
w x22 in 1 ml fractions in test tubes containing 25 ml
of 1 M Tris-HCl, pH 7.5, 85% of activity was eluted
within three fractions and 94% of the activity was
eluted within four fractions. Fractions containing ac-
tivity were pooled and the purified enzyme was
concentrated and desalted by using Centricon 10
 .Amicon ultrafiltration units. The enzymes from E.
coli and 266-6 cells were purified by mixing with the
same anti-C6.5-streptavidin-agarose at 48C overnight,
washing and eluting as described above. The column
was washed extensively with PBS after each use.
Protein was determined using the Bicinchoninic
 . w xacid protein assay kit Sigma 23 . The enzyme was
w xcharacterized by SDS-PAGE 24 followed by zymo-
gram analysis as described by Malburg and Forsberg
w x25 , using low viscosity carboxymethylcellulose
 .CMC as substrate.
Endoglucanase activity was determined by incubat-
ing samples with 1% CMC in 50 mM sodium phos-
phate buffer, pH 6.5 for 20 min unless indicated
.otherwise at 378C and the reducing sugar released
from substrate was quantified by the method of Lever
w x26 . One unit of enzyme activity was defined as the
amount of enzyme releasing 1 mmol of reducing
 .sugars per min, and one milliunit mU of enzyme
activity was defined as the amount of enzyme releas-
ing 1 nmol of reducing sugars per min.
2.5. Protein deglycosylation
Protein glycosylation was detected by incubating
samples with N-glycosidase F or endoglycosidase H
w xat 378C overnight as described by Yang et al. 27 ,
followed by western blotting using a polyclonal anti-
body against C6.5 or zymogram analysis using CMC
as substrate.
2.6. Protease resistance
Enzyme was incubated with a freshly prepared
mixture of four proteases, trypsin, chymotrypsin,
elastase and pancreatin or with each of them 1
. w xmgrml each for 2 h at 378C 28 in PBS buffer,
followed by enzyme assays. Enzyme incubated with
the same amount of bovine albumin served as con-
trol.
2.7. Binding of endoglucanase C6.5 to cellulose
 .Enzyme 20–100 mg in 50 ml of PBS was mixed
with 0.5 ml of pre-washed Avicel PH105 15 mgrml
.in PBS for 1 h at 378C. The bound enzyme was
sedimented by centrifugation at 5000=g for 5 min
with the cellulose and washed with 0.5 ml of PBS
buffer. Binding of the endoglucanase to cellulose was
determined by assaying the activities in both the
unbound fraction and the suspension of the enzyme-
bound cellulose.
3. Results
3.1. Construction of expression plasmids and trans-
fection of CHO and pancreatic 266-6 cells
To express the endoglucanase gene C6.5 and se-
crete the enzyme in CHO cells, the C6.5 sequences
 . Xincluding stop codon was fused 5 to the promoter-
signal peptide coding sequence and 3X to the down
stream end of the Amy-2.2 sequence 105 bp before
the stop codon followed by the polyA sequence Fig.
.1A . The resulting construct SVAC6.5 contained the
SV40 promoterrenhancer, the Amy-2.2 signal pep-
tide coding sequence, the endoglucanase gene C6.5
and the Amy-2.2 polyA signal. The protein product
 .from this fusion gene contained 499 amino acids aa ,
18 of which were from the amylase including a 15 aa
signal peptide, 7 aa from the cloning junction, and
474 aa from the C6.5 endoglucanase, with a predicted
molecular mass of 55.5 kDa, 54.1 kDa for the se-
creted product.
For expression in pancreatic 266-6 cells, the same
C6.5 sequence was fused in-frame with the Amy-2.2
sequence immediately behind the 32nd codon and
cloning junction to give the construct AmyC6.5 con-
taining the Amy-2.2 promoterrenhancer, Amy-2.2
signal peptide coding sequence, the endoglucanase
gene C6.5 and the mouse Amy-2.2 polyA tail Fig.
.1B . This construct encoded a fusion product of 514
aa, with a predicted molecular mass of 57.1 kDa,
55.8 kDa for the secreted product. For selection,
SVAC6.5 was cloned into pSV2-dhfr containing a
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 .mouse dihydrofolate reductase gene dhfr as a selec-
tive marker, and the AmyC6.5 was cloned into
pRSV-gpt containing the E. coli xanthine-guanine
 .phosphoribosyl transferase gene gpt as the selective
marker.
The plasmids containing SVAC6.5 and AmyC6.5
were stably transfected into CHO-dhfry and pancre-
atic 266-6 cells, respectively. pSV2-dhfr and pRSV-
gpt without the endoglucanase insert were transfected
as controls for each system. Analysis of culture fluid
and disrupted cells demonstrated the presence of
endoglucanase activity in SVAC6.5-transformed CHO
cells and AmyC6.5-transformed 266-6 cells. The
plasmid containing AmyC6.5 was also stably trans-
fected into CHO cells to test the specificity of the
pancreatic promoterrenhancer. No activity was de-
tected from this transformed cell line, indicating that
the Amy-2.2 promoter-directed expression of C6.5 is
pancreas specific. No endoglucanase activity was de-
tected from the cells transformed by the control
plasmids pSV2-dhfr or pRSV-gpt.
3.2. PCR and RT-PCR analysis of the transfected cell
lines
Incorporation of the C6.5 transgenes into the
SVAC6.5-transformed CHO and AmyC6.5-trans-
formed 266-6 cells was confirmed by PCR analysis
using a pair of primers that yield a 0.5 kbp fragment
 .Fig. 2A . The transcripts from the transgenes in both
cell lines were also identified by RT-PCR analysis
 .using the same pair of primers Fig. 2B . The CHO
cells transformed with the construct AmyC6.5 showed
a 0.5 kbp PCR product but we were unable to detect
any positive signal in RT-PCR analysis lane 2 in
.Fig. 2C .
3.3. Synthesis of endoglucanase C6.5 in SVAC6.5-
transformed CHO and AmyC6.5-transformed pancre-
atic 266-6 cells
SVAC6.5-transformed CHO cells exhibited a nearly
linear increase in endoglucanase accumulation and
secretion over a 72 h period following subculture,
 .even though cell growth slowed after 24 h Fig. 3 .
The maximum level of endoglucanase activity reached
in a 72 h culture was 35.5 mUrml 1127 mUrmg
.cell protein and more than 89% of the synthesized
Fig. 2. Identification of C6.5 transgene DNA and mRNA in the
transformed cells by PCR and RT-PCR, respectively. Panel A:
PCR products from C6.5 ). Lane 1, PCR negative control; lane
2, 266-6 cell DNA; lane 3, pC6.5 plasmid DNA; lane 4,
AmyC6.5-transformed 266-6 cell DNA; lane 5, SVAC6.5-trans-
formed CHO cell DNA. Panel B: RT-PCR products. Lane 1,
266-6 cell control; lane 2, AmyC6.5-transformed 266-6 cells;
lane 3, no transcriptase control of lane 2; lane 4, SVAC6.5-trans-
formed CHO cells; lane 5, no transcriptase control of lane 4.
Panel C: PCR and RT-PCR products of C6.5 from AmyC6.5-
transformed CHO cells. Lane 1, PCR product for C6.5; lane 2.
RT-PCR product. 5 ml of PCR reaction mixture or 10 ml of
RT-PCR reaction mixture was added in each lane. ) In the
condition used, the primer pair amplifies some non-specific prod-
ucts from the DNA preparations, but much less in quantity
compared to the expected product.
Fig. 3. Synthesis and secretion of the endoglucanase C6.5 from
SVAC6.5-transformed CHO cells. Curves represent activity in
 .  .  .culture fluid B , activity in cells I , and cell protein v . The
activity assays were carried out in 50 mM sodium phosphate
buffer, pH 6.5. Samples of 40 ml were incubated with 1% CMC
 .in total 100 ml at 378C for 1 h. The culture fluid samples were
dialyzed in 50 mM sodium phosphate buffer, pH 6.5 for 24 h
before the assay to remove the sugars in the medium.
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activity was secreted into the culture fluid. The func-
tion of the amylase signal peptide in this system was
further confirmed by N-terminal amino acid sequenc-
ing of the secreted enzyme.
In contrast, the level of endoglucanase activity
produced by the AmyC6.5-transformed 266-6 cells
reached only 0.3 mUrmg cell protein after 72 h of
culture and all of the activity was detected from
culture fluid. No activity was detected in the cell
 .extract. Addition of insulin 0.96, 9.6 or 96 mIUrml
 .or dexamethasone 1, 10 or 100 nM did not signifi-
cantly increase in endoglucanase activity data not
.shown .
The low endoglucanase activity secreted by pan-
creatic cells can not be ascribed to the extra N-termi-
nal amino acids in the enzyme because the same
enzyme synthesized in E. coli using the glutathione
S-transferase expressionrpurification system exhib-
ited greater than 66% of the specific activity of the
enzyme without the extra N-terminal amino acids
 .constructs C and D, Fig. 1 .
3.4. Endoglucanases produced by the transformed
CHO and pancreatic 266-6 cells
Analysis of the proteins in cell extracts and culture
fluid of the SVAC6.5-transformed CHO cells and
AmyC6.5-transformed 266-6 cells by SDS-PAGE and
renaturing zymogram analysis showed that an enzy-
matically active endoglucanase of about 66 kDa was
produced by both transformed CHO and 266-6 cells
 .Fig. 4 . The protein was somewhat larger than the
predicted size of 54.1 kDa for the SVAC6.5 CHO-de-
rived enzyme or 55.8 kDa for the AmyC6.5 266-6-
derived enzyme. Using an antibody against C6.5
endoglucanase, western blot analysis of proteins in
the extracellular culture fluid of CHO cells also
showed a protein with a molecular mass of 66 kDa
 .Fig. 5A . The increased size of the secreted endoglu-
canases from transformed CHO and 266-6 cells com-
pared to that from E. coli suggested post-transla-
tional modifications of the enzyme by both cell lines.
To determine if the C6.5 endoglucanases produced
by these transformed cells undergo glycosylation,
proteins from these cells were treated with two differ-
ent glycosidases and analyzed by western blotting or
zymogram analysis. Treatment of the CHO-derived
endoglucanase with N-glycosidase F reduced the
Fig. 4. SDS-PAGE and zymogram analysis of the endoglucanases
from SVAC6.5-transformed CHO cells and AmyC6.5-trans-
formed 266-6 cells. Panel A: SDS-PAGE. Lane 1, purified
enzyme from E. coli; lane 2, purified enzyme from CHO cells.
Panel B: Zymogram. Lane 1, purified enzyme from E. coli; lane
2, secreted enzyme from CHO cells; lane 3, secreted enzyme
from 266-6 cells. About 1 mg of purified protein was loaded in
each lane of the SDS-gel and 5P10y3 mg of purified enzyme was
loaded in each lane for zymogram analysis, except for the
enzyme from 266-6 cells, less was used. Arrows indicate low
intensity enzyme activity.
molecular mass of the enzyme from 66 kDa to about
56 kDa form. The 60 kDa form seen in Fig. 5A
resulted from incomplete deglycosylation unpub-
.lished results . In contrast, the size of the E. coli-de-
rived enzyme was unaffected by this glycosidase.
Treatment with endoglycosidase H did not change to
the size of the enzymes from either CHO cells or E.
 .coli Fig. 5A . Zymogram analysis of the N-glyco-
sidase F-treated endoglucanase from 266-6 cells
showed, in addition to the glycosylated form, an
active band with a molecular mass of 54 kDa which
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Fig. 5. Deglycosylation of the transgene products from
SVAC6.5-transformed CHO cells and AmyC6.5-transformed 266-
6 cells. Panel A: Western blot detection of CHO-derived en-
doglucanase. Lane 1, purified endoglucanase C6.5 from E. coli;
lane 2, enzyme from transformed CHO culture fluid; lane 3,
CHO-derived enzyme treated with N-glycosidase F; lane 4,
CHO-derived enzyme treated with endoglycosidase H. Approxi-
mately 0.5 mg of purified C6.5 from E. coli or 5 mg of
transformed CHO cell protein was loaded in each lane. Panel B:
Zymogram detection of CHO and 266-6-derived endoglucanases.
Lane 1, purified C6.5 endoglucanase from E. coli; lane 2,
purified endoglucanase from SVAC6.5-transformed CHO cells;
lane 3, N-glycosidase F-treated CHO endoglucanase; lane 4,
purified endoglucanase from AmyC6.5-transformed 266-6 cells
 .an arrow points to the active enzyme ; lane 5, N-glycosidase
F-treated 266-6 endoglucanase an arrow points to the active
. y3enzyme . About 5=10 mg of purified endoglucanase was
loaded into each lane, except less enzyme from 266-6 cells was
used.
is close to that of the unglycosylated enzyme from E.
 .coli Fig. 5B .
3.5. Catalytic properties, resistance to proteolytic
inacti˝ation and cellulose binding of the glycosylated
endoglucanase from transformed CHO cells
In order to investigate the effects of glycosylation
on the activity of the transgenic endoglucanase, the
enzyme from CHO culture fluid was purified to
 .homogenous lane 2 in Fig. 4A by immuno-affinity
chromatography using a specific antibody against
C6.5 endoglucanase. For comparison, the unglycosy-
lated C6.5 endoglucanase was also purified from E.
 .coli by the same method lane 1 in Fig. 4A . The
results showed that the glycosylated enzyme purified
from transformed CHO cells is slightly less active
 .11.8 Urmg than the unglycosylated enzyme from
 .E. coli 15.0 Urmg , and has a slightly lower K ofm
5.33 mgrml compared to 8.02 mgrml for the ungly-
cosylated enzyme.
The glycosylated enzyme from transformed CHO
cells was protease resistant. After 2 h incubation with
cocktail of trypsin, chymotrypsin, pancreatin and
elastase, the glycosylated enzyme increased in spe-
cific activity by 11%, while the unglycosylated en-
zyme remained unchanged no significant difference,
.data not shown . Treatment with each of the four
proteases individually showed that the modest in-
crease of the activity of the glycosylated enzyme was
 .due to chymotrypsin and elastase data not shown .
Both glycosylated and unglycosylated enzyme
bound to cellulose. The glycosylated enzyme was
found to bind to cellulose at a level of 44% under the
conditions tested, while the unglycosylated enzyme
bound to cellulose at a level of 62%.
4. Discussion
In this study, we demonstrated the expression of a
 .Bacillus subtilis endo 1,4 -b-glucanase gene C6.5 in
two different mammalian cell culture systems, CHO
and pancreatic 266-6 cells. The endoglucanases pro-
duced by both transformed cell lines were secreted
into the culture fluid in an active form. The endoglu-
canase secreted from CHO cells was glycosylated
with N-linked oligosaccharides. This is not unex-
w xpected of CHO cells 29 , particularly since the C6.5
endoglucanase contains six potential sites for N-
 . w xglycosylation Asn-X-ThrrSer 30 . Evidence for
N-glycosylation of the CHO-synthesized C6.5 en-
doglucanase is based on the observation that the
endoglucanase is cleaved with N-glycosidase F, which
cleaves all types of N-linked oligosaccharide chains
w x31 , but not by endoglycosidase H which cleaves
w xonly high mannose and hybrid structures 32,33 .
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This pattern of cleavage suggests a complex of N-lin-
ked oligosaccharides rather than N-linked mannose
structures. It is not clear which residues of the en-
zyme are glycosylated. However, the appearance of
two distinct bands after incomplete digestion by N-
glycosidase F suggests that the glycosylation occurs
at least at two sites. These N-glycosylation sites are
probably not close to the catalytic center of the
enzyme because after deglycosylation the resultant
 .smaller protein product 53 kDa retained its catalytic
activity. Furthermore, the size of an active 38 kDa
glucanase fragment which contains the catalytic site
 .was not affected by deglycosylation Fig. 5B . It is
possible that some O-glycans were attached to the
CHO-derived enzyme because the deglycosylated
product was still slightly larger than the E. coli-de-
 .rived enzyme Fig. 5A .
This study has demonstrated for the first time that
the Amy-2.2 promoterrenhancer can direct expres-
sion of a bacterial endoglucanase in pancreatic cells
in culture. The expressed endoglucanase was also
glycosylated with N-linked oligosaccharides. This
contrasts with endoglucanase E of Clostridium ther-
mocellum, which was not glycosylated when ex-
pressed in the pancreas of transgenic mice under the
w xcontrol of the Elastase I promoterrenhancer 34 , but
w xit was glycosylated in CHO cells 6 .
The level of endoglucanase expression directed by
the Amy-2.2 promoterrenhancer in pancreatic 266-6
cells was much lower than SV40-directed expression
in CHO cells, and it was not enhanced by either
insulin or dexamethasone, agents previously shown to
w xenhance pancreatic expression 17,35,36 . The ab-
sence of induction by insulin and dexamethasone
may reflect the overall low activity expressed from
this cell line. The additional 25 amino acids in the
endoglucanase secreted by 266-6 cells can not be the
origin of the low activity in this cell line because the
same enzyme synthesized in E. coli exhibited greater
than 66% of the specific activity of the endoglu-
canase without the extra amino acids see Section
.3.3 . The 266-6 cell line expresses the endogenous
 . w xamylase gene at a very low level -1% 9 , imply-
ing a lower capability of Amy-2.2 promoter-directed
expression in this cell line. However, the amylase
activity in 266-6 cells is 2000-fold higher than en-
doglucanase activity in the AmyC6.5-transformed
266-6 cell line 600 mUrmg vs. 0.3 mUrmg cell
.protein . In terms of protein production, the amylase
is 466-fold higher than the endoglucanase, based on a
w xspecific activity of 211 Urmg for amylase 37 and
 .13.3 Urmg for the endoglucanase this study . This
 .could be due to a number of factors including a a
low percentage of cells carrying the transgene result-
ing from less stringent selection compared to CHO
 .cells; b glycosylation could direct secretion of the
endoglucanase into a non-secretory pathway, possibly
w xto the lysosome 38 . Future experiments will address
these factors.
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